ArticleMultidisciplinary respiratory medicine2013
CD24+/CD38- as new prognostic marker for non-small cell lung cancer.
Article in Multidisciplinary respiratory medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identification of Biomarkers and Molecular Pathways Implicated in Smoking and COVID-19 Associated Lung Cancer Using Bioinformatics and Machine Learning Approaches.International journal of environmental research and public health · 2024Article
- Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model.Translational cancer research · 2024Article
- Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.International journal of molecular sciences · 2024Article
- Extracellular vesicles in non-small cell lung cancer stemness and clinical applications.Frontiers in immunology · 2024Review
- Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study.Iranian journal of pathology · 2024Article
- Cellular Effects of Selected Unsymmetrical Bisacridines on the Multicellular Tumor Spheroids of HCT116 Colon and A549 Lung Cancer Cells in Comparison to Monolayer Cultures.International journal of molecular sciences · 2023Article
- The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance.International journal of molecular sciences · 2022Review
- CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells.International journal of oncology · 2019Article
- CD38 as a PET Imaging Target in Lung Cancer.Molecular pharmaceutics · 2017Article
- Stemness-Related Markers in Cancer.Cancer translational medicine · 2017Article
- Targeting Lung Cancer Stem Cells: Research and Clinical Impacts.Frontiers in oncology · 2017Review
- Role of CD24 in anoikis resistance of ovarian cancer cells.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Article
- High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.Disease markers · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer.
methodsIn this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel.
resultsWe demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM.
conclusionsWe report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.